Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib
- 12 May 2016
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 178 (1), 153-155
- https://doi.org/10.1111/bjh.14118
Abstract
No abstract availableKeywords
Funding Information
- Janssen-Cilag Ltd
This publication has 6 references indexed in Scilit:
- The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone lossBone, 2014
- The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast MaturationPublished by Elsevier BV ,2008
- Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM SignalsCell, 2008
- Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemiaAnnals of Hematology, 1994
- Micro‐osteoclast resorption as a characteristic feature of B‐cell malignancies other than multiple myelomaBritish Journal of Haematology, 1990
- B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma: Study of nine casesAmerican Journal Of Medicine, 1987